Azithromycin for acute lower respiratory tract infections

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Laopaiboon, Malinee ^a   Panpanich, Ratana ^b   Swa Mya, Kyaw ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c University of Medicine   (Myanmar)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; ANTIINFECTIVE AGENT;

ADVERSE EVENT; BACTERIAL CLEARANCE; BACTERIAL PNEUMONIA; BRONCHITIS; CHRONIC BRONCHITIS; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ACUTE DISEASE; DRUG COMBINATION; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; TREATMENT FAILURE;

ACUTE DISEASE; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHITIS; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TREATMENT FAILURE;

EID: 84936960165     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001954.pub4     Document Type: Review

References (57)

1. Balmes P, Clerc G, Dupont B, Labram C, Pariente R, Poirier R. Comparative study of azithromycin and amoxycillin/clavulanic acid in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology & Infectious Diseases 1991;10(5):437-9. [: CN-00077568]
2. Beghi G, Berni F, Carratu L, Casalini A, Consigli G, D'Antò M, et al. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. Journal of Chemotherapy 1995;7(2):146-52. [: CN-00117950]
3. Biebuyck XA. Comparison of azithromycin and co-amoxyclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Journal of Internal Medical Research 1996;24(5):407-18. [: CN-00168989]
4. Daniel R. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group. Journal of International Medical Research 1991;19(5):373-83. [: CN-00080152]
5. Ferwerda A, Moll HA, Hop WCJ, Kouwenberg JM, Tjon Pian Gi CV, Robben SG, et al. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 2001;47:441-6.
6. Gris P. Once-daily, 3 day azithromycin versus a three-times-daily, 10-day course of co-amoxyclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. Journal of Antimicrobial Chemotherapy 1996;37:93-101.
7. Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatric Infectious Diseases Journal 1998;17:865-71.
8. Hoepelman AIM, Sips AP, Helmond JLM, Barneveld PWC, Neve AJ, Zwinkels M, et al. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl E):147-52.
9. Hoepelman IM, Mollers MJ, Schie MH, Greefhorst AP, Schlösser NJ, Sinninghe Damsté EJ, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. International Journal of Antimicrobial Agents 1998;9:141-6.
10. Kogan R, Martinez MA, Rubilar L, Paya E, Quevedo I, Puppo H, et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatric Pulmonology 2003;35(2):91-8.
11. Mertens JC, van Barneveld PW, Asin HR, Ligtvoet E, Visser MR, Branger T, et al. Double-blind randomized study comparing the efficacies and safeties of a short (3 day) course of azithromycin and a 5 day course of amoxycillin in patients with acute exacerbations of chronic bronchitis. Antimicrobial Agents and Chemotherapy 1992;36(7):1456-9. [: CN-00086554]
12. Sevieri G, Roggi G, Monacci A. A comparison between amoxycillin clavulanic acid and azithromycin in exacerbations of chronic bronchitis sustained by Haemophilus influenzae [Confronto Fra Amoxycillina-Acido Clavulanico E Azitromicina Nelle Riacutizzazione Di Bronchite Cronica Sostenuta Da Haemofilus Influenzae]. Minerva Pneumologica 1993;32(2):67-70.
13. Whitlock W. Multicenter comparison of azithromycin and amoxycillin/clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease. Current Therapeutic Research Clinical and Experimental 1995;56(10):985-95. [: CN-00174186]
14. Wubbel L, Muniz L, Ahmed A, Trujillo M, Carubelli C, Abramo T, et al. Etiology and treatment of community acquired pneumonia in ambulatory children. Pediatric Infectious Disease Journal 1999;18(2):98-104.
15. Zachariah J. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1996;37(Suppl):103-13.
16. Zheng S, Li X. Research of amoxicillin/clavulanic in acute purulent exacerbation of chronic bronchitis compare with azithromycin. Journal of Clinical Pulmonary Medicine 2002;7(3):5-6.
17. Berry V, Rhorburn CE, Knott SJ, Woodnutt G. Bacteriological efficacies of three macrolides compared with those of amoxycillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenza. Antimicrobial Agents and Chemotherapy 1998;42(12):3193-9.
18. Bohte R, van't Wout JW, Lobatto S, Blusse van Oud Alblas A, Boekhout M, Nauta EH. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community acquired pneumonia. European Journal of Clinical Microbiology & Infectious Diseases 1995;14(3):182-7.
19. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. Journal of Antimicrobial Chemotherapy 1993;31(Suppl E):153-62.
20. Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007;132(2):447-55.
21. Ficnar B, Huzjak N, Oreskovic K, Matrapazovski M, Kilnar I. Azithromycin: 3 day versus 5 day course in the treatment of respiratory tract infections in children. Journal of Chemotherapy 1997;9(1):38-43.
22. Gomez Campdera JA, Navarro Gomez ML, et al. Azithromycin in the treatment of ambulatory pneumonia in children [Azitromycina en el tratamiento de las neumonias ambulatorias en la infancia]. Acta Pediatrica Espanola 1996;54(8):554-62.
23. Laurent K. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1996;37(Suppl C):115-24.
24. Lauvau D, Verbist L. An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxyclav in the treatment of upper and lower respiratory tract infections in children. Journal of International Medical Research 1997;25(5):285-95. [: CN-00197916]
25. Maimon N, Nopmaneejumruslers C, Marras C. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. European Respiratory Journal 2008;31:1068-76.
26. Morandini G, Perduca M, Zannini G, Foschino MP, Miragliotta G, Carnimeo NS. Clinical efficacy of azithromycin in lower respiratory tract infections. Journal of Chemotherapy 1993;5(1):32-6.
27. Morris PS, Gadil G, McCallum GB, Wilson CA, Smith-Vaughan HC, Torzillo P, et al. Single-dose azithromycin versus seven days of amoxycillin in the treatment of acute otitis media in Aboriginal children (AATAAC): a double blind, randomised controlled trial. Medical Journal of Australia 2010;192(1):24-9.
28. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. International Journal of Antimicrobial Agents 2004;24(2):181-4.
29. Roord J, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective open randomized study comparing efficacies and safeties of a 3 day course of azithromycin and a 10 day course of erythromycin in children with community acquired acute lower respiratory tract infections. Antimicrobial Agents and Chemotherapy 1996;40(12):2765-8.
30. Austrian R. Confronting drug-resistant pneumococci. Annals of Internal Medicine 1994;121:807-9.
31. Bariffi F, Sanduzzi A, Ponticiello A. Epidemiology of lower respiratory tract infections. Journal of Chemotherapy 1995;7(4):263-76.
32. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clinical Infectious Diseases 1998;26:811-38.
33. Berntsson E, Lagergard T, Strannegard O, Trollfors B. Etiology of community-acquired pneumonia in outpatients. European Journal of Clinical Microbiology 1986;5:446.
34. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998;352:1295-302.
35. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drug 1996;51(3):483-505.
36. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiology for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990;69(5):307-16.
37. Goldstein FW, Acar JF. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA Collaborative Surveillance Study: The Alexandes Project Collaborative Groups. Journal of Antimicrobial Chemotherapy 1996;38(Suppl A):71-84.
38. Graffelman AW, Neven AK, Cessie SI, Kroes ACM, Springer MP, Peterhans Broek PJ. Pathogens involved in lower respiratory tract infections in general practice. British Journal of General Practice 2004;54:15-9.
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
40. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Available from www.cochrane-handbook.org, 2011.
41. Huchon G, Woodhead M, Gialdroni-Grassi G, et al. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Journal 1998;11:986-91.
42. Knutson D, Braun C. Diagnosis and management of acute bronchitis. American Family Physician 2002;65(10):2039-44.
43. Langille DB, Yates L, Marrie TJ. Serological investigation of pneumonia as it presents to the physician's office. Canadian Journal of Infectious Diseases 1993;4:328.
44. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
45. Legnani D. Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections. Diagnostic Microbiology and Infectious Disease 1997;27:41-7.
46. Lieberman D, Schlaeffer F, Bolden I, Lieberman D, Horowitz S, Friedman MG, et al. Multiple pathogen in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996;51(2):179-84.
47. Mandell LA. Antibiotics for pneumonia therapy. Medical Clinics of North America 1994;78(5):997-1014.
48. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. American Journal of Medicine 1996;101:508-15.
49. Meehan TP, Fine Mj, Krunholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
51. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infectious Agents and Disease 1994;3(5):266-73.
52. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I. The value of routine microbial investigation in community-acquired pneumonia. Respiratory Medicine 1991;85:313-7.
53. Woodhead M, Gialdroni-Grassi G, Huchon GL, Leophonte P, Manresa F, Schaberg T. Use of investigations in lower respiratory tract infection in the community: a European survey. European Respiratory Journal 1996;9(8):1596-600.
54. Laopaiboon M, Panpanich R, Lerttrakarnnon P. Azithromycin for acute lower respiratory tract infections. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: ]
55. Panpanich R, Lerttrakarnnon P. Azithromycin for acute lower respiratory tract infections. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: ]
56. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: ]
57. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: ]